As of June 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $104.2 million, which provides projected cash runway into the fourth quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LRMR:
- Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
- Is LRMR a Buy, Before Earnings?
- Guggenheim views Larimar Therapeutics update ‘very favorably’
- These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
- Larimar receives FDA clearance to proceed to 50mg in Phase 2 trial of CTI-1601